Cargando…
CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
BACKGROUND: MYCN amplification as a common genetic alteration that correlates with a poor prognosis for neuroblastoma (NB) patients. However, given the challenge of directly targeting MYCN, indirect strategies to modulate MYCN by interfering with its cofactors are attractive in NB treatment. Althoug...
Autores principales: | Zhou, Yang, Yan, Hui, Zhou, Qiang, Wang, Penggao, Yang, Fang, Yuan, Ziqiao, Du, Qianming, Zhai, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352605/ https://www.ncbi.nlm.nih.gov/pubmed/37461251 http://dx.doi.org/10.1002/ctm2.1328 |
Ejemplares similares
-
Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN
por: Zhang, Xiaoling, et al.
Publicado: (2023) -
MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023) -
Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020) -
Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020) -
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)